Program
Triamcinolone
Also written as “intravitreal triamcinolone injection”, “Triamcinolone (Optional)” and “Triamcinolone Injection”.
Its studies are mostly in Cataract · Acne Vulgaris · Melanosis · Macular Edema · Rhinitis, Allergic, Perennial, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| ACOM Labs | 10 open or running | no phasesince Dec 6, 2023 | Dec 6, 2023 | none ahead |
| Research Insight | 11 open or running | phase 4since Oct 30, 2025 | Oct 30, 2025 | Dec 31, 2026phase 4 · NCT07276802 |
| Sanofi | 10 open or running | phase 3since Aug 18, 2005 | Aug 18, 2005 | none ahead |
| The Emmes | 10 open or running | phase 3since Mar 3, 2005 | Mar 3, 2005 | none ahead |
Also a collaborator on its studies: AbbVie.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 3, 2005First study: phase 3 study in Macular EdemaNew to The EmmesThe Emmes · NCT00105027 · 682 enrolled · United States
- Aug 18, 2005Sanofi's first study: phase 3 study in Rhinitis, Allergic, PerennialNew to SanofiSanofi · NCT00132925 · 460 enrolled · United States
- Dec 6, 2023ACOM Labs's first study: no phase study in Acne VulgarisNew to ACOM LabsACOM Labs · NCT06170593 · 20 enrolled · United States
- Oct 30, 2025Research Insight's first study: phase 4 study in Post Cataract SurgeryNew to Research InsightResearch Insight · NCT07276802 · 40 planned · United States
Ahead
- Dec 31, 2026Primary completion: phase 4 study in Post Cataract SurgeryResearch Insight · NCT07276802
TargetBeta
“Glucocorticoid receptor agonist”ChEMBL 37, by rule
Other programs on NR3C1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Dexamethasonerule | AbbVie | phase 4 | 174 |
| Budesoniderule | AstraZeneca | phase 4 | 167 |
| fluticasone furoaterule | GlaxoSmithKline | phase 4 | 97 |
| Prednisonerule | Johnson & Johnson | phase 4 | 65 |
| Beclomethasonerule | Chiesi Farmaceutici | phase 4 | 46 |
| Prednisolonerule | Sanofi | phase 4 | 34 |
| betamethasone dipropionaterule | LEO Pharma | phase 4 | 27 |
| Methylprednisolonerule | Pfizer | phase 4 | 23 |
| dexamethasone phosphaterule | eyegate-pharmaceuticals-inc | phase 4 | 21 |
| vamorolonerule | reveragen-biopharma-inc | phase 4 | 11 |
| Betamethasonerule | LEO Pharma | phase 4 | 9 |
| relacorilantrule | Corcept Therapeutics | phase 3 | 22 |
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07276802Post Cataract Surgery · United States | 4 | Not yet recruiting | Research Insight | Dec 31, 2026 | 40 |
| NCT06170593Acne Vulgaris · United States | – | Completed | ACOM Labs | Jan 31, 2023 | 20 |
| NCT00132925Rhinitis, Allergic, Perennial · United States | 3 | Completed | Sanofi | 460 | |
| NCT00105027Macular Edema · United States | 3 | Completed | The Emmes | Feb 2009 | 682 |
How it is read
Names in the registry
- “intravitreal triamcinolone injection”, 2 entries
- “Triamcinolone (Optional)”, 1 entry
- “Triamcinolone Injection”, 1 entry
- “arbutin, tretinoin, triamcinolone”, 1 entry
- “Triamcinolone”, 1 entry
Conditions, from the studies’ own filings
- Cataract, 1 study
- Acne Vulgaris, 1 study
- Melanosis, 1 study
- Macular Edema, 1 study
- Rhinitis, Allergic, Perennial, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.